Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRISPR Therapeutics Moves Into Off-The-Shelf CAR-T Lead, But Durability Test Awaits

Allogene Remains A Rival Despite Safety Hiatus

Executive Summary

Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.

You may also be interested in...



Single Patient Safety Concern Hits Allogene’s Off-The-Shelf CAR-T

Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.

Leucid Bio Unveils ‘Parallel CAR-T’ Platform Targeting Solid Tumors

The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.

Failure Brings Atea and Roche’s COVID-19 Pill Moonshot Down To Earth

An attempt to show efficacy even in younger people with mild COVID-19 symptoms has fallen flat in Phase II, and AT-527 will now lag behind rivals Merck and Pfizer.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel